Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder
- PMID: 38105655
- DOI: 10.1002/cncr.35010
Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder
Abstract
Background: Depression is common in patients with cancer and is associated with lower treatment adherence and reduced quality of life. Antidepressants and psychotherapy have limited success in improving depression among patients with cancer. This study explored the safety, feasibility, and efficacy of psilocybin-assisted therapy in patients with cancer and major depressive disorder.
Methods: This phase 2, open-label trial enrolled patients with curable and noncurable cancer and major depressive disorder at a single community oncology practice site. A single 25-mg dose of psilocybin was administered simultaneously to cohorts of three to four participants with individual (4.25 hours in 1:1 therapist-to-patient ratio) and group therapeutic support (3.75 hours) before, during, and after psilocybin administration. Outcomes included depression severity, anxiety, pain, demoralization, and disability.
Results: Thirty participants completed the study. No psilocybin-related serious adverse events occurred; treatment-related adverse events (e.g., nausea, headache) were generally mild and expected. There were no laboratory or electrocardiogram abnormalities. No suicidality was reported. Efficacy was suggested with a robust reduction in depression severity scores from baseline to posttreatment of 19.1 points (95% CI, 22.3 to -16.0; p < .0001) by week 8. Eighty percent of participants demonstrated a sustained response to psilocybin treatment; 50% showed full remission of depressive symptoms at week 1, which was sustained for 8 weeks.
Conclusions: Psilocybin-assisted therapy in group cohort administration was safe and feasible in patients with cancer and depression. Efficacy was suggested based on clinically meaningful reductions in depressive symptoms. The novel, group-oriented format, compact delivery time, community cancer center setting, and one-to-one therapist-to-patient ratio could also add to therapeutic gains and efficiency of administration.
Trial registration: NCT04593563.
Plain language summary: Depression is common in patients with cancer and associated with lower treatment adherence, reduced quality of life, and limited response to antidepressants and psychotherapy. We conducted a phase 2 trial to study a single dose of psilocybin administered in a group therapy setting with one-to-one therapist-to-participant psychological support to patients with curable and noncurable cancer and major depressive disorder. Findings of the study showed safety (no treatment-related serious adverse events or suicidality) with psilocybin and suggested efficacy, with a significant reduction in depression severity scores from baseline to posttreatment. Further investigation is warranted.
Keywords: cancer; depression; group therapy; major depressive disorder; psilocybin; psychedelics; psychotherapy.
© 2023 American Cancer Society.
Similar articles
-
HOPE: A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer.J Pain Symptom Manage. 2023 Sep;66(3):258-269. doi: 10.1016/j.jpainsymman.2023.06.006. Epub 2023 Jun 10. J Pain Symptom Manage. 2023. PMID: 37302533
-
Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin.Med. 2024 Mar 8;5(3):190-200.e5. doi: 10.1016/j.medj.2024.01.005. Epub 2024 Feb 14. Med. 2024. PMID: 38359838 Clinical Trial.
-
Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial.JAMA Psychiatry. 2024 Jun 1;81(6):555-562. doi: 10.1001/jamapsychiatry.2023.4685. JAMA Psychiatry. 2024. PMID: 38055270 Free PMC article. Clinical Trial.
-
Psychedelic Therapy: A Primer for Primary Care Clinicians-Psilocybin.Am J Ther. 2024 Mar-Apr 01;31(2):e121-e132. doi: 10.1097/MJT.0000000000001724. Am J Ther. 2024. PMID: 38518269 Review.
-
The role of psilocybin in depressive disorders.Curr Med Res Opin. 2024 Oct;40(10):1793-1808. doi: 10.1080/03007995.2024.2396536. Epub 2024 Aug 28. Curr Med Res Opin. 2024. PMID: 39177339 Review.
Cited by
-
Psychedelic Drugs in Mental Disorders: Current Clinical Scope and Deep Learning-Based Advanced Perspectives.Adv Sci (Weinh). 2025 Apr;12(15):e2413786. doi: 10.1002/advs.202413786. Epub 2025 Mar 20. Adv Sci (Weinh). 2025. PMID: 40112231 Free PMC article. Review.
-
Cosmology of belonging: The role of community in the therapeutic use of psychedelics.Palliat Support Care. 2025 Jan 21;23:e27. doi: 10.1017/S1478951524001688. Palliat Support Care. 2025. PMID: 39834311 Free PMC article.
-
Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment.Med Sci Monit. 2025 Aug 9;31:e948302. doi: 10.12659/MSM.948302. Med Sci Monit. 2025. PMID: 40781763 Free PMC article. Review.
-
Psilocybin-Assisted Group Psychotherapy + Mindfulness Based Stress Reduction (MBSR) for Frontline Healthcare Provider COVID-19 Related Depression and Burnout: A Randomized Clinical Trial.medRxiv [Preprint]. 2025 Jan 1:2024.12.31.24319806. doi: 10.1101/2024.12.31.24319806. medRxiv. 2025. PMID: 39802794 Free PMC article. Preprint.
-
Psilocybin-Assisted suppoRtive psychoTherapy IN the treatment of prolonged Grief (PARTING) trial: protocol for an open-label pilot trial for cancer-related bereavement.BMJ Open. 2025 Apr 15;15(4):e095992. doi: 10.1136/bmjopen-2024-095992. BMJ Open. 2025. PMID: 40233965 Free PMC article.
References
REFERENCES
-
- Mitchell AJ, Chan M, Bhatti H, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12(2):160-174. doi:10.1016/s1470-2045(11)70002-x
-
- Arrieta O, Angulo LP, Núñez-Valencia C, et al. Association of depression and anxiety on quality of life, treatment adherence, and prognosis in patients with advanced non-small cell lung cancer. Ann Surg Oncol. 2013;20(6):1941-1948. doi:10.1245/s10434-012-2793-5
-
- Pinquart M, Duberstein PR. Depression and cancer mortality: a meta-analysis. Psychol Med. 2010;40(11):1797-1810. doi:10.1017/s0033291709992285
-
- Ostuzzi G, Matcham F, Dauchy S, Barbui C, Hotopf M. Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev. 2018;2018(4):CD011006. doi:10.1002/14651858.cd011006.pub3
-
- Li X, Frye MA, Shelton RC. Review of pharmacological treatment in mood disorders and future directions for drug development. Neuropsychopharmacology. 2012;37(1):77-101. doi:10.1038/npp.2011.198
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical